Cholangiocarcinoma Clinical Trials in Boston, Massachusetts
8 recruitingBoston, Massachusetts
Showing 1–8 of 8 trials
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 1
A Study of MGC028 in Participants With Advanced Solid Tumors
CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 1
A Study of PHST001 in Advanced Solid Tumors
Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 2
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
CholangiocarcinomaBile Duct CancerCholangiocarcinoma Non-resectable+2 more
Beth Israel Deaconess Medical Center30 enrolled1 locationNCT05655949
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting
Phase 1
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
CholangiocarcinomaAdvanced Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital70 enrolled1 locationNCT06302621
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Solid TumorIntrahepatic CholangiocarcinomaLocally Advanced Cholangiocarcinoma+1 more
Tyra Biosciences, Inc40 enrolled4 locationsNCT06160752